Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Return on Assets (2018 - 2025)

Denali Therapeutics (DNLI) has disclosed Return on Assets for 8 consecutive years, with 0.45% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Assets fell 15.0% to 0.45% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.45%, a 15.0% decrease, with the full-year FY2024 number at 0.33%, down 22.0% from a year prior.
  • Return on Assets was 0.45% for Q3 2025 at Denali Therapeutics, down from 0.39% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.04% in Q1 2021 to a low of 0.45% in Q3 2025.
  • A 5-year average of 0.2% and a median of 0.22% in 2022 define the central range for Return on Assets.
  • Biggest YoY gain for Return on Assets was 38bps in 2021; the steepest drop was -26bps in 2021.
  • Denali Therapeutics' Return on Assets stood at 0.2% in 2021, then dropped by -21bps to 0.25% in 2022, then skyrocketed by 46bps to 0.13% in 2023, then plummeted by -126bps to 0.3% in 2024, then tumbled by -50bps to 0.45% in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Return on Assets are 0.45% (Q3 2025), 0.39% (Q2 2025), and 0.34% (Q1 2025).